---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References"
description: "Reference list for the formulary evidence report on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide. 165 cited documents."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References

<a id="references"></a>

## 5 References

1. [Abida et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6459218/)
2. [Agarwal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37285865/)
3. [Agarwal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40683290/)
4. [Akeega prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216793s001lbl.pdf)
5. [Alumkal and Ellis (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13552191/)
6. [American Cancer Society (2026)](https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html)
7. [American Cancer Society signs and symptoms (2026)](https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/signs-symptoms.html)
8. [Annala et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33836265/)
9. [Antonarakis et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4201502/)
10. [Antonarakis et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7186583/)
11. [Appukkuttan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10394191/)
12. [Attard et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6118405/)
13. [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer)
14. [Beltran et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4777652/)
15. [Bosch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13287194/)
16. [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27Nubeqa%25%27)
17. [Caram et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7959094/)
18. [Castro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311294/)
19. [Castro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832950/)
20. [Clarke et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319800/)
21. [ClinicalTrials.gov NCT03480646](https://clinicaltrials.gov/study/NCT03480646)
22. [ClinicalTrials.gov NCT03480646 results](https://clinicaltrials.gov/study/NCT03480646?tab=results)
23. [ClinicalTrials.gov NCT04179864](https://clinicaltrials.gov/study/NCT04179864)
24. [ClinicalTrials.gov NCT04179864 results](https://clinicaltrials.gov/study/NCT04179864?tab=results)
25. [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421)
26. [ClinicalTrials.gov NCT06551324](https://clinicaltrials.gov/study/NCT06551324)
27. [ClinicalTrials.gov NCT07028853](https://clinicaltrials.gov/study/NCT07028853)
28. [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)
29. [CMS Enhancing Oncology Model](https://www.cms.gov/priorities/innovation/innovation-models/enhancing-oncology-model)
30. [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)
31. [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf)
32. [CMS OPPS Addendum B (2026)](https://www.cms.gov/files/zip/October-2026-OPPS-Addendum-B.zip)
33. [Corn et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6858999/)
34. [Daemen et al. (2021)](https://oricpharma.com/wp-content/uploads/2021/03/ORIC-944-AACR2021-Abstract1131-FINAL.pdf)
35. [Daemen et al. (2025)](https://oricpharma.com/wp-content/uploads/2025/04/AACR2025_ORIC-944-poster_Final.pdf)
36. [de Bono et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20888992/)
37. [de Bono et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28844372/)
38. [de Bono et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32343890/)
39. [de Feria Cardet et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33341285/)
40. [de Wit et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31566937/)
41. [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)
42. [eCQI Resource Center CMS645v9 (2026)](https://ecqi.healthit.gov/ecqm/ec/2026/cms0645v9)
43. [eCQI Resource Center CMS645v9 specification (2026)](https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS645-v9.0.000-QDM.html)
44. [Erleada prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210951s024lbl.pdf)
45. [FDA Tazverik safety alert (2026)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik)
46. [Fendler et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10027805/)
47. [Fizazi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3090685/)
48. [Fizazi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32926841/)
49. [Fizazi et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10064172/)
50. [Fizazi et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10641914/)
51. [Fizazi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40441170/)
52. [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/)
53. [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/)
54. [Freedland et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10500004/)
55. [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)
56. [Friedman (2024)](https://oricpharma.com/wp-content/uploads/2024/04/AACR2024_ORIC-944_NDoH.pdf)
57. [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)
58. [Gandaglia et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24132735/)
59. [George et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42431822/)
60. [Gharzai et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/38320030/)
61. [Giri et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40239123/)
62. [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/)
63. [Hagiwara et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23146970/)
64. [Halabi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872320/)
65. [Hofman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33581798/)
66. [Hofman et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38043558/)
67. [Hussain et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32955174/)
68. [Jain et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218467/)
69. [Jevtana prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201023s026lbl.pdf)
70. [Joyce et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37416955/)
71. [Joyce et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11192241/)
72. [Kantoff et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20818862/)
73. [Kaye et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10113111/)
74. [Kaye et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38204397/)
75. [Kaye et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11217864/)
76. [Keytruda prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)
77. [Khalaf et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31727538/)
78. [Kirby et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21995694/)
79. [Ku et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5367887/)
80. [Kunst et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12552925/)
81. [Kuppen et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31883940/)
82. [Kwan et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40425844/)
83. [Lloyd et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26686802/)
84. [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf)
85. [Mahmud et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13348720/)
86. [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf)
87. [Matsubara et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.5046)
88. [Matsubara et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.195)
89. [McDougall et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4786354/)
90. [McKay et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42836510/)
91. [Morgans et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9284907/)
92. [Morgans et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11365817/)
93. [Morris et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4881370/)
94. [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)
95. [Morris et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11851234/)
96. [Narayan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39232487/)
97. [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)
98. [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)
99. [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C188381?include=full)
100. [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)
101. [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)
102. [ORIC Pharmaceuticals (2020)](https://oricpharma.com/news/oric-pharmaceuticals-expands-precision-oncology-pipeline-with-exclusive-worldwide-license-to-highly-selective-allosteric-prc2-inhibitors-from-mirati-therapeutics/)
103. [ORIC Pharmaceuticals AACR preclinical data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings-at-the-2026-american-association-for-cancer-re/)
104. [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/)
105. [ORIC Pharmaceuticals early combination data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-highlights-for-2024-and-anticipated-upcoming-milestones/)
106. [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)
107. [ORIC Pharmaceuticals expanded access policy](https://oricpharma.com/patients/)
108. [ORIC Pharmaceuticals first quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates/)
109. [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm)
110. [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)
111. [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)
112. [ORIC Pharmaceuticals initial phase 1b data release (2024)](https://oricpharma.com/news/oric-pharmaceuticals-provides-initial-phase-1b-data-for-oric-944-operational-highlights-for-2023-and-anticipated-upcoming-milestones/)
113. [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm)
114. [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm)
115. [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/)
116. [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)
117. [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)
118. [ORIC Pharmaceuticals second quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operational-updates/)
119. [Oster et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23884473/)
120. [Pankov et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/08/Rinzimetostat_20AACR_20Poster_201.pdf)
121. [Parekh et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41033927/)
122. [Parker et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23863050/)
123. [Pluvicto prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215833s037lbl.pdf)
124. [Provenge prescribing information](https://www.fda.gov/media/78511/download)
125. [Rao et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7662417/)
126. [Rathkopf et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5885186/)
127. [Raval et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40670254/)
128. [Raval et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41266184/)
129. [Robinson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4484602/)
130. [Rubraca prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209115s014s015lbl.pdf)
131. [Saad et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12359855/)
132. [Sanyal and Rendon (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13033869/)
133. [Sartor et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446332/)
134. [Saylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31990618/)
135. [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/)
136. [Scher et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872347/)
137. [Schweizer et al. (2024)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5061)
138. [Schweizer et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.LBA138)
139. [Shevrin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42161163/)
140. [Shore et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33906368/)
141. [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/)
142. [Shore et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13401553/)
143. [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)
144. [Su et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7870786/)
145. [Swami et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37248148/)
146. [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)
147. [Talzenna prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211651s014lbl.pdf)
148. [Tannock et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15470213/)
149. [Taxotere prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020449s086lbl.pdf)
150. [Tazverik prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211723s005lbl.pdf)
151. [Teppala et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11570197/)
152. [Teppala et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38977196/)
153. [von Amsberg et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41807148/)
154. [Watson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4771416/)
155. [WHO Drug Information Proposed INN List 133 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl133.pdf)
156. [WHO Drug Information Recommended INN List 95 (2026)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl95.pdf)
157. [Xgeva prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125320s225lbl.pdf)
158. [Xofigo prescribing information (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203971s016lbl.pdf)
159. [Xtandi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203415s026lbl.pdf)
160. [Xu et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3625962/)
161. [Yee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10811023/)
162. [Yu et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39787437/)
163. [Yuen et al. (2025)](https://oricpharma.com/wp-content/uploads/2025/10/ENA2025_ORIC-944-ARi-CSPC-Poster.pdf)
164. [Zometa prescribing information (2018)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021223s041lbl.pdf)
165. [Zytiga prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202379s035lbl.pdf)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
